Correlation Between Visa and Provectus Biopharmaceutica

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Visa and Provectus Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Visa and Provectus Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Visa Class A and Provectus Biopharmaceuticals, you can compare the effects of market volatilities on Visa and Provectus Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Visa with a short position of Provectus Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Visa and Provectus Biopharmaceutica.

Diversification Opportunities for Visa and Provectus Biopharmaceutica

0.64
  Correlation Coefficient

Poor diversification

The 3 months correlation between Visa and Provectus is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Visa Class A and Provectus Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Provectus Biopharmaceutica and Visa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Visa Class A are associated (or correlated) with Provectus Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Provectus Biopharmaceutica has no effect on the direction of Visa i.e., Visa and Provectus Biopharmaceutica go up and down completely randomly.

Pair Corralation between Visa and Provectus Biopharmaceutica

If you would invest  11.00  in Provectus Biopharmaceuticals on January 20, 2024 and sell it today you would earn a total of  0.00  from holding Provectus Biopharmaceuticals or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy4.55%
ValuesDaily Returns

Visa Class A  vs.  Provectus Biopharmaceuticals

 Performance 
       Timeline  
Visa Class A 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Visa Class A has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Visa is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.
Provectus Biopharmaceutica 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Provectus Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Provectus Biopharmaceutica is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Visa and Provectus Biopharmaceutica Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Visa and Provectus Biopharmaceutica

The main advantage of trading using opposite Visa and Provectus Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Visa position performs unexpectedly, Provectus Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Provectus Biopharmaceutica will offset losses from the drop in Provectus Biopharmaceutica's long position.
The idea behind Visa Class A and Provectus Biopharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Complementary Tools

Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk